Meritage Portfolio Management Acquires Shares of 84,784 Roche Holding AG $RHHBY

Meritage Portfolio Management acquired a new stake in shares of Roche Holding AG (OTCMKTS:RHHBY) during the fourth quarter, HoldingsChannel.com reports. The firm acquired 84,784 shares of the company’s stock, valued at approximately $4,372,000.

A number of other hedge funds have also recently modified their holdings of the business. Boston Common Asset Management LLC grew its stake in shares of Roche by 1.9% during the third quarter. Boston Common Asset Management LLC now owns 368,553 shares of the company’s stock valued at $15,049,000 after buying an additional 6,720 shares during the last quarter. Altrius Capital Management Inc grew its stake in shares of Roche by 4.0% during the third quarter. Altrius Capital Management Inc now owns 198,278 shares of the company’s stock valued at $8,290,000 after buying an additional 7,659 shares during the last quarter. Bard Financial Services Inc. grew its stake in shares of Roche by 1.3% during the third quarter. Bard Financial Services Inc. now owns 138,650 shares of the company’s stock valued at $5,797,000 after buying an additional 1,800 shares during the last quarter. Diversified Trust Co. grew its stake in shares of Roche by 1.8% during the fourth quarter. Diversified Trust Co. now owns 58,927 shares of the company’s stock valued at $3,051,000 after buying an additional 1,046 shares during the last quarter. Finally, Diversified Trust Co grew its stake in shares of Roche by 0.5% during the third quarter. Diversified Trust Co now owns 57,881 shares of the company’s stock valued at $2,363,000 after buying an additional 310 shares during the last quarter.

Roche Trading Up 0.1%

Shares of OTCMKTS:RHHBY opened at $51.33 on Tuesday. Roche Holding AG has a 52-week low of $35.07 and a 52-week high of $60.85. The business’s 50 day moving average is $53.34 and its 200 day moving average is $50.59. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. TD Cowen reaffirmed a “hold” rating on shares of Roche in a research note on Tuesday, February 10th. Barclays raised Roche from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Zacks Research raised Roche from a “strong sell” rating to a “hold” rating in a research note on Monday, January 5th. Wolfe Research reaffirmed an “outperform” rating on shares of Roche in a research note on Thursday, February 26th. Finally, Argus raised Roche from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. Five investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Roche has a consensus rating of “Hold” and an average target price of $57.00.

Roche Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.